US Stock MarketDetailed Quotes
YTEN Yield10 Bioscience
- 0.313
- -0.188-37.50%
15min DelayTrading Nov 25 10:00 ET
216.46KMarket Cap-15P/E (TTM)
0.313High0.313Low226Volume0.313Open0.500Pre Close70.63Turnover0.04%Turnover RatioLossP/E (Static)692.68KShares17.25652wk High-0.03P/B194.48KFloat Cap0.31352wk Low--Dividend TTM622.35KShs Float1714175.571Historical High--Div YieldTTM0.00%Amplitude0.313Historical Low0.312Avg Price1Lot Size
Yield10 Bioscience Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 81.36%-574K | 66.14%-903K | 11.72%-10.07M | 44.12%-1.71M | 3.37%-2.61M | -21.32%-3.08M | 14.02%-2.67M | -23.25%-11.4M | -23.22%-3.06M | -35.64%-2.7M |
| Net income from continuing operations | 12.03%-3.24M | 34.64%-2.47M | -6.55%-14.46M | 1.12%-3.27M | -6.79%-3.73M | -6.91%-3.68M | -13.54%-3.78M | -22.98%-13.57M | -10.84%-3.3M | -45.50%-3.49M |
| Operating gains losses | ---- | ---- | -18.80%108K | ---- | ---- | ---- | ---- | 18.75%133K | ---- | ---- |
| Depreciation and amortization | -21.05%60K | -4.35%66K | 10.27%290K | 10.61%73K | 4.35%72K | 10.14%76K | 16.95%69K | 19.55%263K | 20.00%66K | 21.05%69K |
| Deferred tax | ---- | ---- | --0 | --0 | ---- | ---- | ---- | 371.43%165K | 1,063.64%128K | 80.00%18K |
| Other non cash items | 2,000.00%126K | 19.23%124K | -21.63%308K | 13.73%116K | -17.17%82K | -93.81%6K | 9.47%104K | 9.78%393K | 9.68%102K | 10.00%99K |
| Change In working capital | 2,202.17%2.12M | 102.73%967K | 400.58%2.09M | 285.06%966K | 365.55%554K | -55.56%92K | 195.59%477K | -11.74%-695K | -196.59%-522K | 154.59%119K |
| -Change in receivables | --0 | --0 | -82.14%30K | --0 | --0 | --0 | 87.50%30K | 297.65%168K | 135.94%46K | -129.55%-13K |
| -Change in prepaid assets | 87.06%-11K | -635.14%-198K | 315.63%345K | 205.66%224K | 89.89%169K | -142.86%-85K | 1,950.00%37K | -353.97%-160K | -7,166.67%-212K | 147.22%89K |
| -Change in payables and accrued expense | 695.89%1.74M | -168.25%-374K | 1,285.79%2.17M | 505.43%896K | 186.44%507K | -12.40%219K | 240.87%548K | -33.58%-183K | -415.71%-221K | 198.88%177K |
| -Change in other current liabilities | -290.48%-164K | -16.67%-161K | 12.31%-456K | -14.07%-154K | 8.96%-122K | 66.93%-42K | -11.29%-138K | -12.31%-520K | -11.57%-135K | -12.61%-134K |
| -Change in other working capital | --550K | --1.7M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 81.36%-574K | 66.14%-903K | 11.72%-10.07M | 44.12%-1.71M | 3.37%-2.61M | -21.32%-3.08M | 14.02%-2.67M | -23.25%-11.4M | -23.22%-3.06M | -35.64%-2.7M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 0 | -77.18%1.95M | -101.33%-20K | -99.97%1K | -100.50%-18K | 2,352.27%1.98M | 286.15%8.52M | 122.04%1.5M | 247.32%3.49M |
| Net PPE purchase and sale | --0 | --0 | 70.13%-46K | ---20K | 104.76%1K | 5.26%-18K | 92.11%-9K | 18.52%-154K | --0 | -90.91%-21K |
| Net investment purchase and sale | --0 | --0 | -77.05%1.99M | --0 | --0 | --0 | 7,557.69%1.99M | 297.68%8.68M | 122.17%1.5M | 245.62%3.52M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | --0 | -77.18%1.95M | -101.33%-20K | -99.97%1K | -100.50%-18K | 2,352.27%1.98M | 286.15%8.52M | 122.04%1.5M | 247.32%3.49M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -108.96%-326K | 758.87%1.21M | 18,670.27%6.87M | 0 | 13,543.48%3.09M | 3.64M | 1,107.14%141K | -100.23%-37K | 0 | -15.00%-23K |
| Net issuance payments of debt | ---- | ---- | --967K | --0 | ---33K | ---- | ---- | --0 | --0 | --0 |
| Net common stock issuance | --0 | --0 | --103K | ---5.84M | --5.84M | ---79K | --182K | --0 | --0 | --0 |
| Proceeds from stock option exercised by employees | -101.36%-37K | --1.21M | --5.84M | ---- | ---- | --2.72M | --0 | --0 | ---- | ---- |
| Net other financing activities | ---- | ---- | -10.81%-41K | --0 | --0 | --0 | -192.86%-41K | 64.08%-37K | --0 | -15.00%-23K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -108.96%-326K | 758.87%1.21M | 18,670.27%6.87M | --0 | 13,543.48%3.09M | --3.64M | 1,107.14%141K | -100.23%-37K | --0 | -15.00%-23K |
| Net cash flow | ||||||||||
| Beginning cash position | -20.69%1.64M | -49.16%1.33M | -53.16%2.62M | -26.40%3.08M | -24.51%2.6M | -13.34%2.07M | -53.16%2.62M | 51.70%5.59M | -71.87%4.19M | -78.35%3.44M |
| Current changes in cash | -266.36%-900K | 156.62%308K | 57.11%-1.25M | -10.82%-1.73M | -37.32%482K | -49.81%541K | 83.02%-544K | -252.43%-2.92M | 83.19%-1.56M | 176.44%769K |
| Effect of exchange rate changes | 107.14%1K | 233.33%4K | 33.33%-36K | -350.00%-18K | 96.30%-1K | 46.15%-14K | -200.00%-3K | -500.00%-54K | -233.33%-4K | -58.82%-27K |
| End cash Position | -71.35%745K | -20.69%1.64M | -49.16%1.33M | -49.16%1.33M | -26.40%3.08M | -24.51%2.6M | -13.34%2.07M | -53.16%2.62M | -53.16%2.62M | -71.87%4.19M |
| Free cash flow | 81.47%-574K | 66.26%-903K | 12.49%-10.11M | 43.47%-1.73M | 4.15%-2.61M | -21.12%-3.1M | 16.79%-2.68M | -22.41%-11.56M | -21.17%-3.06M | -35.95%-2.72M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data